U.S. markets close in 1 hour 25 minutes
  • S&P 500

    4,055.52
    +37.75 (+0.94%)
     
  • Dow 30

    33,930.99
    +213.90 (+0.63%)
     
  • Nasdaq

    11,535.54
    +141.72 (+1.24%)
     
  • Russell 2000

    1,922.86
    +37.14 (+1.97%)
     
  • Crude Oil

    78.51
    +0.61 (+0.78%)
     
  • Gold

    1,945.50
    +6.30 (+0.32%)
     
  • Silver

    23.82
    +0.09 (+0.37%)
     
  • EUR/USD

    1.0875
    +0.0019 (+0.17%)
     
  • 10-Yr Bond

    3.5200
    -0.0310 (-0.87%)
     
  • GBP/USD

    1.2337
    -0.0016 (-0.13%)
     
  • USD/JPY

    130.0660
    -0.2920 (-0.22%)
     
  • BTC-USD

    23,137.68
    +284.59 (+1.25%)
     
  • CMC Crypto 200

    525.45
    +6.66 (+1.28%)
     
  • FTSE 100

    7,771.70
    -13.17 (-0.17%)
     
  • Nikkei 225

    27,327.11
    -106.29 (-0.39%)
     

Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer

Thermo Fisher Scientific Inc. TMO recently launched the Thermo Scientific Ramina Process Analyzer— a new Raman spectroscopic analyzer for process monitoring in various applications like biopharmaceutical manufacturing. This easy-to-use system is intended to eliminate the complexity of performing Raman spectroscopy measurements, allowing users with any degree of experience to conduct measurements with great precision and accuracy.

The Ramina Process Analyzer delivers non-destructive and continuous analysis without requiring sample preparation. It features a rapid system setup and allows for deployment within 15 minutes, yielding spectral data on target analytes in seconds. The compact system employs a variety of patented probes to increase the speed and sensitivity of results, facilitating fully automated in situ measurements to compute concentrations in a reaction vessel.

This latest launch is likely to bolster Thermo Fisher’s Laboratory Products and Biopharma Services business.

More on the News

The Ramina Process Analyzer comes with a Raman spectrometer and fiber optic probe, as well as a portable monitor, mouse, keyboard and laser safety goggles to enable data collection. The Ramina system is factory calibrated to ensure that it is ready for use without any delay. Its solid-state construction provides long-term stability, allowing for continuous and precise measurements, removing the need for frequent calibration. This system also lets users utilize multiple systems in a parallel manner to test different reaction vessels at the same time or combine several probes in a single vessel.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Per management, the Ramina Process Analyzer offers an almost effortless technique for conducting precise in-situ Raman measurements, enabling customers to generate real-time data where and when required. The analyzer’s compact and portable design, together with its user-friendly operation, will help lower time-to-results without taking up too much laboratory space.

Industry Prospects

Per a report by MarketsandMarkets, the global Raman spectroscopy market is set to witness a CAGR of 7.4% during 2021-2026. Factors such as growing focus on drug development in healthcare and increasing uptake of Raman spectroscopy in clinical applications are fuelling market growth.

Given the market prospects, Thermo Fisher’s latest launch of the Ramina Process Analyzer seems well-timed.

Notable Developments

Thermo Fisher engaged in a number of significant developments in March 2022.

The company launched the Ion Torrent Genexus Dx Integrated Sequencer. This CE-IVD marked automated, next-generation sequencing (NGS) platform delivers results within a single day. The platform’s automated workflow reduces user intervention and the possibility of human error, making NGS accessible to all laboratories.

The company announced the availability of the non-hazardous InhibiSURE Viral Inactivation Medium formula in Europe. This novel viral transport medium facilitates the collection and rapid inactivation of the SARS-CoV-2 virus while stabilizing viral RNA at ambient temperature for transportation and use in in-vitro diagnostic testing procedures. The use of this inactivation medium also enhances laboratory throughput by eliminating the need for further inactivation steps.

Share Price Performance

The stock has outperformed its industry over the past year. It has rallied 24.6% compared to the industry’s growth of 0.3%.

Zacks Rank and Key Picks

Currently, Thermo Fisher carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical space are Owens & Minor, Inc. OMI, NextGen Healthcare, Inc. NXGN and McKesson Corporation MCK.

Owens & Minor has a long-term earnings growth rate of 8.8%. Owens & Minor’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 29.5%, on average. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Owens & Minor has outperformed the industry over the past year. OMI has gained 9.3% against a 15.9% industry decline in the said period.

NextGen has an estimated long-term growth rate of 5%. NextGen’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.5%. It currently carries a Zacks Rank #2.

NextGen has outperformed the industry over the past year. NXGN has gained 17.4% compared with the industry’s 38.2% fall over the past year.

McKesson has a long-term earnings growth rate of 11.8%. McKesson’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 20.6%, on average. It presently carries a Zacks Rank #2.

McKesson has outperformed the industry over the past year. MCK has gained 64.5% in the said period compared with 9.3% growth of the industry.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Owens & Minor, Inc. (OMI) : Free Stock Analysis Report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

McKesson Corporation (MCK) : Free Stock Analysis Report

NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research